<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00001723</url>
  </required_header>
  <id_info>
    <org_study_id>980111</org_study_id>
    <secondary_id>98-CH-0111</secondary_id>
    <nct_id>NCT00001723</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Xenical in Children and Adolescents With Obesity-Related Diseases</brief_title>
  <official_title>Safety and Efficacy of Orlistat (Xenical, Hoffmann LaRoche) in African American and Caucasian Children and Adolescents With Obesity-Related Comorbid Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jack Yanovski</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obesity is a condition affecting one-third off the U.S. population and is a major risk actor
      for the development of Type 2 diabetes, hyperlipidemia (increased levels of fat in the
      blood), hypertension (high blood pressure), and other disorders of the heart and lungs.
      Individuals with the onset of obesity during childhood or adolescence are at an increased
      risk of obesity-related, diseases, both during adolescence and later in adult life.

      African American girls and women are at an increased risk for obesity, and have substantial
      rates of obesity-related diseases and causes of death. Further, many African American adult
      women fail to respond to many of the therapeutic approaches used to treat obesity. At present
      there are no medical therapies proven effective for the correction of severe obesity in
      children or adolescents.

      One medication that may have a favorable risk-benefit ratio in pediatric populations is
      Orlistat (Xenical, Hoffmann LaRoche). Orlistat works by preventing the action of enzymes in
      the digestive process, interfering with the absorption of approximately 1/3 of the fat eaten
      in the diet. Xenical appears to be effective for reducing weight and obesity-associated
      diseases in obese adults.

      Researchers propose to determine the safety, tolerability, and efficacy of Xenical in 12-17
      year old severely obese African American and Caucasian children and adolescents who have one
      or more obesity-related disease (hypertension, hyperlipidemia, sleep apnea, hepatic
      steatosis, insulin resistance, impaired glucose tolerance, or Type 2 diabetes).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Obesity is a condition affecting one-third of the adult U.S. population and is a major risk
      factor for the development of Type 2 diabetes, hyperlipidemia, hypertension, and other
      cardiovascular and respiratory disorders. Individuals with the onset of obesity during
      childhood or adolescence are at increased risk for obesity-related, comorbid conditions, both
      during adolescence and later in life. African American girls and women are at particular risk
      for obesity, and have substantial rates of obesity-related morbidity and mortality. Further,
      African American adult women have a less satisfactory response to many therapeutic approaches
      used to treat obesity. At present, there are no medical therapies proven effective for the
      amelioration of severe obesity in children or adolescents. One medication that may have a
      favorable risk-benefit ratio in pediatric populations is orlistat (Xenical(Trademark),
      Hoffmann LaRoche). Orlistat acts by inhibiting gastrointestinal lipases, interfering with the
      absorption of approximately 1/3 of ingested dietary fat. Orlistat appears to be effective for
      reducing weight and obesity-associated comorbidities in obese adults. We propose to determine
      the safety, tolerability, and efficacy of orlistat in 12-17 year-old severely obese African
      American and Caucasian children and adolescents who have one or more obesity-related
      comorbidity (hypertension, hyperlipidemia, sleep apnea, hepatic steatosis,
      insulin-resistance, impaired glucose tolerance, or Type 2 diabetes). Under this protocol, we
      have conducted an open-label pilot study of orlistat in twenty subjects, suggesting orlistat
      has a similar side effect profile in adolescents as in adults. We wish to determine the
      safety and efficacy of orlistat in reducing obesity-related comorbidities using a randomized,
      double-blind, placebo-controlled clinical trial. All study participants will be enrolled in a
      psycho-educational weight loss program that includes nutrition education,
      cognitive-behavioral self-monitoring strategies, and promotion of physical activity. We will
      also study the effects of orlistat on fat preferences, and study the influence of genetic
      variables on energy expenditure and weight loss during treatment. A group of healthy,
      non-overweight children and adolescents will complete questionnaires and exercise studies as
      a control group for interpretation of results in overweight children and adolescents, but
      will not undergo phlebotomy or receive any medication.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 1998</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in BMI Standard Deviation Score</measure>
    <time_frame>baseline to 6 months</time_frame>
    <description>Body Mass index standard deviation score calculated for age and sex according to Centers for Disease Control standards. See: Kuczmarski RJ, Ogden CL, Guo SS, Grummer-Strawn LM, Flegal KM, Mei Z et al. 2000 CDC Growth Charts for the United States: methods and development. Vital Health Stat 11 2002; (246): 1-190.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Body Weight</measure>
    <time_frame>baseline to 6 months</time_frame>
    <description>Weight in kg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body Mass Index</measure>
    <time_frame>baseline to 6 months</time_frame>
    <description>BMI is calculated in kg/m2. Change from baseline to 6 months of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body Fat (kg)</measure>
    <time_frame>baseline to 6 months</time_frame>
    <description>body fat distribution measures obtained from Dual-energy X-ray Absorptiometry (DEXA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Race on Change in Weight (kg)</measure>
    <time_frame>baseline to 6 months</time_frame>
    <description>Difference in change of weight in kg according to race (Non-Hispanic White versus Non-Hispanic Black)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Hypertension</condition>
  <condition>Metabolic Disease</condition>
  <condition>Obesity</condition>
  <condition>Sleep Apnea Syndrome</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo 120 mg TID x 6 months plus a behavioral weight loss program</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Orlistat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Orlistat 120 mg TID for 6 months plus a behavioral weight loss program</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Orlistat</intervention_name>
    <description>Subjects receive drug for 6 months plus a 12 week intensive behavioral weight los program. Subjects return for monthly visits for 3 more months.</description>
    <arm_group_label>Orlistat</arm_group_label>
    <other_name>Xenical (orlistat)capsules</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects receive drug for 6 months plus a 12 week intensive behavioral weight los program. Subjects return for monthly visits for 3 more months.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo capsule</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

        Good general health. Individuals taking medications for obesity-related comorbid conditions
        will not be excluded.

        Obesity: body mass index for age and triceps skinfold above the 95th percentile (determined
        by NHANES I age-, sex-, and race- specific data). All subjects will be required to be over
        60 kg in body weight.

        Evidence for a quantifiable obesity-related comorbidity. Examples include: systolic or
        diastolic hypertension (determined by age-specific charts); frank Type 2 diabetes, impaired
        glucose tolerance assessed by oral glucose tolerance testing; hyperinsulinemia (defined as
        a fasting insulin greater than 15 mIU/mL); significant hyperlipidemia (total cholesterol
        greater than 200 mg/dL, LDL cholesterol greater than 129 mg/dL or fasting triglycerides
        greater than 200 mg/dL); hepatic steatosis (SGPT or SGOT above normal range with negative
        hepatitis studies) or sleep apnea documented by a sleep study.

        Age 12 to 17 years at the start of the study.

        For girls with childbearing potential, a negative pregnancy test before taking and while
        taking study medication. Sexually active females must be using an effective form of birth
        control. These methods include total abstinence (no sex), oral contraceptives (&quot;the pill&quot;),
        an intrauterine device (IUD), levonogestrol implants (Norplant), or medroxyprogesterone
        acetate injections (Depo-provera shots). If one of these cannot be used, contraceptive foam
        with a condom is recommended.

        Race of all four grandparents self-identified as either all Caucasian or all African
        American.

        EXCLUSION CRITERIA:

        Volunteers will be excluded (and referred to non-experimental treatment programs) for the
        following reasons:

        Presence of renal, hepatic (other than obesity-related steatosis), gastrointestinal, most
        endocrinologic (e.g., Cushing syndrome), or pulmonary disorders (other than either asthma
        not requiring continuous medication or sleep apnea-related disorders);

        Adolescent girls who are pregnant, who are currently nursing an infant, or who are having
        unprotected intercourse;

        Individuals who have, or whose parent or guardians have, current substance abuse or a
        psychiatric disorder or other condition which, in the opinion of the investigators, would
        impede competence or compliance or possibly hinder completion of the study;

        Subjects who regularly use prescription medications unrelated to the complications of
        obesity. Oral contraceptive use will be permitted, provided the contraceptive has been used
        for at least two months before starting study medication. The use of over-the-counter and
        prescription medications will be reviewed on a case-by-case basis; depending on the
        medication, subjects who have continued to take prescription medication for at least 3
        months prior to study entry may be eligible;

        Recent use (within six months) of anorexiant medications for the purpose of weight
        reduction;

        Inability to undergo MRI (e.g., volunteers with metal within their bodies including cardiac
        pacemakers, neural pacemakers, aneurysmal clips, shrapnel, ocular foreign bodies, cochlear
        implants, non-detachable electronic or electromechanical devices such as infusion pumps,
        nerve stimulators, bone growth stimulators, etc. that are contraindications).

        For pilot study participants, hypersensitivity or allergy to methylene blue. Individuals
        with documented G6PD deficiency will be excluded.

        INCLUSION CRITERIA: HEALTHY CONTROL CHILDREN AND ADOLESCENTS:

        Volunteers will qualify for inclusion if they meet the following criteria:

          1. Good general health.

          2. Age 12-17 years at study entry.

          3. Body mass index (BMI) for age above the 5th percentile and below 85th percentile,
             which is considered normal weight by CDC growth chart standards.

          4. For females with childbearing potential, a negative pregnancy test at initial
             evaluation.

          5. Race of all four grandparents self-identified as either all Caucasian or all African
             American.

        EXCLUSION CRITERIA: HEALTHY CONTROL CHILDREN AND ADOLESCENTS:

        Volunteers will be excluded for the following reasons:

          1. Presence of past or present medical problems which would impair performance during the
             exercise tests;

          2. Females who are pregnant, or who are currently nursing an infant;

          3. Individuals who have, or whose parent or guardian has, current substance abuse or a
             psychiatric disorder or other condition that in the opinion of the investigators would
             impede competence or possibly hinder completion of the study;

          4. Recent weight change of more than 3% of body weight in the past two months;

          5. Recent use (within six months) of anorexiant medications for the purpose of weight
             reduction;

          6. Physical impairments that would prevent completion of either the walk/run test or the
             cycle test.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jack A Yanovski, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_1998-CH-0111.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Kuczmarski RJ, Flegal KM, Campbell SM, Johnson CL. Increasing prevalence of overweight among US adults. The National Health and Nutrition Examination Surveys, 1960 to 1991. JAMA. 1994 Jul 20;272(3):205-11.</citation>
    <PMID>8022039</PMID>
  </reference>
  <reference>
    <citation>Drent ML, Larsson I, William-Olsson T, Quaade F, Czubayko F, von Bergmann K, Strobel W, Sjöström L, van der Veen EA. Orlistat (Ro 18-0647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study. Int J Obes Relat Metab Disord. 1995 Apr;19(4):221-6.</citation>
    <PMID>7627244</PMID>
  </reference>
  <reference>
    <citation>Must A, Jacques PF, Dallal GE, Bajema CJ, Dietz WH. Long-term morbidity and mortality of overweight adolescents. A follow-up of the Harvard Growth Study of 1922 to 1935. N Engl J Med. 1992 Nov 5;327(19):1350-5.</citation>
    <PMID>1406836</PMID>
  </reference>
  <reference>
    <citation>Chanoine JP, Hampl S, Jensen C, Boldrin M, Hauptman J. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA. 2005 Jun 15;293(23):2873-83. Erratum in: JAMA. 2005 Sep 28;294(12):1491.</citation>
    <PMID>15956632</PMID>
  </reference>
  <results_reference>
    <citation>McDuffie JR, Calis KA, Uwaifo GI, Sebring NG, Fallon EM, Frazer TE, Van Hubbard S, Yanovski JA. Efficacy of orlistat as an adjunct to behavioral treatment in overweight African American and Caucasian adolescents with obesity-related co-morbid conditions. J Pediatr Endocrinol Metab. 2004 Mar;17(3):307-19.</citation>
    <PMID>15112907</PMID>
  </results_reference>
  <results_reference>
    <citation>McDuffie JR, Calis KA, Booth SL, Uwaifo GI, Yanovski JA. Effects of orlistat on fat-soluble vitamins in obese adolescents. Pharmacotherapy. 2002 Jul;22(7):814-22.</citation>
    <PMID>12126214</PMID>
  </results_reference>
  <results_reference>
    <citation>McDuffie JR, Calis KA, Uwaifo GI, Sebring NG, Fallon EM, Hubbard VS, Yanovski JA. Three-month tolerability of orlistat in adolescents with obesity-related comorbid conditions. Obes Res. 2002 Jul;10(7):642-50.</citation>
    <PMID>12105286</PMID>
  </results_reference>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 1999</study_first_submitted>
  <study_first_submitted_qc>November 3, 1999</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 1999</study_first_posted>
  <results_first_submitted>October 11, 2012</results_first_submitted>
  <results_first_submitted_qc>November 15, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 18, 2012</results_first_posted>
  <last_update_submitted>November 15, 2012</last_update_submitted>
  <last_update_submitted_qc>November 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</investigator_affiliation>
    <investigator_full_name>Jack Yanovski</investigator_full_name>
    <investigator_title>Section Chief, Section on Growth and Obesity, PDEGEN, NICHD</investigator_title>
  </responsible_party>
  <keyword>Dyslipidemia</keyword>
  <keyword>Race</keyword>
  <keyword>Body Fat</keyword>
  <keyword>Visceral Fat</keyword>
  <keyword>Sleep Apnea</keyword>
  <keyword>Fat-Soluble Vitamins</keyword>
  <keyword>Type 2 Diabetes</keyword>
  <keyword>Obesity</keyword>
  <keyword>Childhood Obesity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Orlistat</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Accrual for RCT began in 1999 and ended in 2008. All subjects were screened at the NIH Clinical Center.</recruitment_details>
      <pre_assignment_details>Most subjects screened but not enrolled (101) did not have an obesity-related comorbid condition (i.e., hypertension or dyslipidemia). 16 met a medical exclusion, and 13 declined participation after undergoing initial evaluation.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Orlistat</title>
          <description>Orlistat 120 mg TID for 6 months plus a behavioral weight loss program
Orlistat : Subjects receive drug for 6 months plus a 12 week intensive behavioral weight los program. Subjects return for monthly visits for 3 more months.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Matching placebo 120 mg TID x 6 months plus a behavioral weight loss program
Placebo : Subjects receive drug for 6 months plus a 12 week intensive behavioral weight los program. Subjects return for monthly visits for 3 more months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
                <participants group_id="P2" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="87"/>
                <participants group_id="P2" count="84"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of family interest</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>medication intolerance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Orlistat</title>
          <description>Orlistat 120 mg TID for 6 months plus a behavioral weight loss program
Orlistat : Subjects receive drug for 6 months plus a 12 week intensive behavioral weight los program. Subjects return for monthly visits for 3 more months.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Matching placebo 120 mg TID x 6 months plus a behavioral weight loss program
Placebo : Subjects receive drug for 6 months plus a 12 week intensive behavioral weight los program. Subjects return for monthly visits for 3 more months.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="100"/>
            <count group_id="B2" value="100"/>
            <count group_id="B3" value="200"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.65" spread="1.38"/>
                    <measurement group_id="B2" value="14.52" spread="1.46"/>
                    <measurement group_id="B3" value="14.59" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in BMI Standard Deviation Score</title>
        <description>Body Mass index standard deviation score calculated for age and sex according to Centers for Disease Control standards. See: Kuczmarski RJ, Ogden CL, Guo SS, Grummer-Strawn LM, Flegal KM, Mei Z et al. 2000 CDC Growth Charts for the United States: methods and development. Vital Health Stat 11 2002; (246): 1-190.</description>
        <time_frame>baseline to 6 months</time_frame>
        <population>Multiple imputation analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Orlistat</title>
            <description>Orlistat 120 mg TID for 6 months plus a behavioral weight loss program
Orlistat : Subjects receive drug for 6 months plus a 12 week intensive behavioral weight los program. Subjects return for monthly visits for 3 more months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo 120 mg TID x 6 months plus a behavioral weight loss program
Placebo : Subjects receive drug for 6 months plus a 12 week intensive behavioral weight los program. Subjects return for monthly visits for 3 more months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in BMI Standard Deviation Score</title>
          <description>Body Mass index standard deviation score calculated for age and sex according to Centers for Disease Control standards. See: Kuczmarski RJ, Ogden CL, Guo SS, Grummer-Strawn LM, Flegal KM, Mei Z et al. 2000 CDC Growth Charts for the United States: methods and development. Vital Health Stat 11 2002; (246): 1-190.</description>
          <population>Multiple imputation analysis</population>
          <units>Standard Deviation Score</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.12" spread="0.02"/>
                    <measurement group_id="O2" value="-0.06" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Body Weight</title>
        <description>Weight in kg</description>
        <time_frame>baseline to 6 months</time_frame>
        <population>Multiple imputation analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Orlistat</title>
            <description>Orlistat 120 mg TID for 6 months plus a behavioral weight loss program
Orlistat : Subjects receive drug for 6 months plus a 12 week intensive behavioral weight los program. Subjects return for monthly visits for 3 more months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo 120 mg TID x 6 months plus a behavioral weight loss program
Placebo : Subjects receive drug for 6 months plus a 12 week intensive behavioral weight los program. Subjects return for monthly visits for 3 more months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Body Weight</title>
          <description>Weight in kg</description>
          <population>Multiple imputation analysis</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.9" spread="0.7"/>
                    <measurement group_id="O2" value="-0.6" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Body Mass Index</title>
        <description>BMI is calculated in kg/m2. Change from baseline to 6 months of treatment</description>
        <time_frame>baseline to 6 months</time_frame>
        <population>Muliple imputation analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Orlistat</title>
            <description>Orlistat 120 mg TID for 6 months plus a behavioral weight loss program
Orlistat : Subjects receive drug for 6 months plus a 12 week intensive behavioral weight los program. Subjects return for monthly visits for 3 more months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo 120 mg TID x 6 months plus a behavioral weight loss program
Placebo : Subjects receive drug for 6 months plus a 12 week intensive behavioral weight los program. Subjects return for monthly visits for 3 more months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Body Mass Index</title>
          <description>BMI is calculated in kg/m2. Change from baseline to 6 months of treatment</description>
          <population>Muliple imputation analysis</population>
          <units>kg per square meter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.44" spread="0.26"/>
                    <measurement group_id="O2" value="-0.50" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Body Fat (kg)</title>
        <description>body fat distribution measures obtained from Dual-energy X-ray Absorptiometry (DEXA)</description>
        <time_frame>baseline to 6 months</time_frame>
        <population>Multiple Imputation analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Orlistat</title>
            <description>Orlistat 120 mg TID for 6 months plus a behavioral weight loss program
Orlistat : Subjects receive drug for 6 months plus a 12 week intensive behavioral weight los program. Subjects return for monthly visits for 3 more months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo 120 mg TID x 6 months plus a behavioral weight loss program
Placebo : Subjects receive drug for 6 months plus a 12 week intensive behavioral weight los program. Subjects return for monthly visits for 3 more months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Body Fat (kg)</title>
          <description>body fat distribution measures obtained from Dual-energy X-ray Absorptiometry (DEXA)</description>
          <population>Multiple Imputation analysis</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.2" spread="0.55"/>
                    <measurement group_id="O2" value="-1.7" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Race on Change in Weight (kg)</title>
        <description>Difference in change of weight in kg according to race (Non-Hispanic White versus Non-Hispanic Black)</description>
        <time_frame>baseline to 6 months</time_frame>
        <population>Multiple imputation analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Orlistat - Non-Hispanic Blacks</title>
            <description>Change in weight for Non-Hispanic Black participants treated with orlistat</description>
          </group>
          <group group_id="O2">
            <title>Orlistat - Non- Hispanic Whites</title>
            <description>Change in weight for Non-Hispanic White participants treated with orlistat</description>
          </group>
          <group group_id="O3">
            <title>Placebo - Non-Hispanic Blacks</title>
            <description>Change in weight for Non-Hispanic Black participants treated with placebo</description>
          </group>
          <group group_id="O4">
            <title>Placebo - Non-Hispanic Whites</title>
            <description>Change in weight for Non-Hispanic White participants treated with placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Race on Change in Weight (kg)</title>
          <description>Difference in change of weight in kg according to race (Non-Hispanic White versus Non-Hispanic Black)</description>
          <population>Multiple imputation analysis</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.126" spread="0.812"/>
                    <measurement group_id="O2" value="-3.742" spread="1.046"/>
                    <measurement group_id="O3" value="0.415" spread="0.835"/>
                    <measurement group_id="O4" value="-1.580" spread="1.013"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months of randomized treatment</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Orlistat</title>
          <description>Orlistat 120 mg TID for 6 months plus a behavioral weight loss program Orlistat : Subjects receive drug for 6 months plus a 12 week intensive behavioral weight los program. Subjects return for monthly visits for 3 more months.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Matching placebo 120 mg TID x 6 months plus a behavioral weight loss program Placebo : Subjects receive drug for 6 months plus a 12 week intensive behavioral weight los program. Subjects return for monthly visits for 3 more months.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE_4.03</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemia - pharmacy error in preparing insulin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Left lower quadrant pain and vomiting - admitted overnight</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>CTCAE_4.03</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="95" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="94" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>ear disorders (otitis, earache, ear pain)</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>eye disorders (change in vision, conjunctivitis, styes)</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>abdominal pain or cramping</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>bloating or gas</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>BORBORYGMI</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Controlled discharge of oil without stool</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Decreased frequency of bowel movements</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>fatty-appearing stools</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>flatulence (passage of gas)</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>flatus with discharge</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>frequent urge for bowel movement</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>hiccups</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Increased frequency of bowel movements</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>oily spotting</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>rectal bleeding - hemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>soft or deliquescent stools</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>stomach pain or cramps</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Stools almost all liquid with very few solid parts</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Stools hard and in the shape of small pellets</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Stools mixed with fat or with a separate oily layer</sub_title>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>uncontrolled passage of stool or oil</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Urgent, but controlled, need to produce stools</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>feeling cold</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>increased sweating</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>increased thirst</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>sinusitis, post-nasal drip or nasal stuffiness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>unusual tiredness or weakness (fatigue)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>sinusitis, post-nasal drip or nasal stuffiness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>decrease in appetite</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>muscle pain, stiffness, cramps, or ache</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>migraine headaches</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>mental depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>dysuria or UTI</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>nocturia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma symptoms</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>skin rash</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jack A. Yanovski, MD, PhD, Chief SGO, PDEGEN</name_or_title>
      <organization>National Institute of Child Health and Human Development, NIH</organization>
      <phone>301-496-4686</phone>
      <email>yanovskj@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

